When the sun is out after a long winter, every one loves it. But not the people of Canary Islands. Tourists there are being warned about the "unusually high risk" of UV rays this week. The Ministry of Health for this holiday destination has urged both, residents and visitors to take extra precautions and preventative measures to limit the impact of sun exposure over their body and skin.

The Ministry observed Aemet, Spain's national weather agency for the forecast which showed higher than normal UV or ultraviolet radiation levels in the region. It is in this backdrop that everyone in the region are requested to be extra careful when they are out in the sun. UV levels are set to reach 7, which is a 'high risk' in La Palma, El Hierro, La Gomera and Gran Canaria. Other regions like Tenerife, Fuerteventura and Lanzarote are expected to reach a level 6, which is also classed as 'high risk'.

UV Index Explained

As per the World Health Organization (WHO), a UV index is a measure of the level of UV radiation, which ranges from zero upward. The higher the UVI, the greater potential for damage to skin and eye and the less time it takes for harm to occur, notes WHO.

The range 1 to 2 represents a low risk, 2 to 5 is moderate, 6 to 7 is at high risk, 8 to 10 is at very high and anything over 11 is extremely risky for anyone to stay out.

UV radiation levels fluctuate throughout the day, with the highest values occurring during the four-hour period around solar noon. The reported UV Index (UVI) typically reflects this daily peak. Depending on geographic location and the use of daylight saving time, solar noon falls between 12 p.m. and 2 p.m. In some countries, sun protection advisories are issued when UV levels are expected to reach 3 or higher, as exposure at these levels increases the risk of skin damage, making protective measures essential.

What happens to you when you are out in sun for too long?

While sun bathing is good, being out in the sun when the UVI indicates a high or very high risk, may cause you health concerns. It can lead to sunburn, premature skin aging, incresed risk of skin cancer, eye damage and in severe cases, heat related disease.

Sunburn

It is one of the most common skin injury which happens when there is excess exposure to UV radiation from the sun. This happens when the UV radiation directly damages the DNA skin cells. These damaged cells die and shed, this is why people experience peeling after getting a sunburn.

Dehydration

This is also a common occurrence when your body loses too many fluids or electrolytes. It can also interfere with your normal body functions. You may feel dehydrated, especially when you are out in the sun, but not well hydrated. The most common symptoms are dizziness, fatigue and headache on hot days.

Hyponatremia

This is an electrolyte disorder in which your body experiences low sodium in blood. The symptoms could lead to nausea, confusion and even weakness. There are extreme cases when one may have seizures, slip into coma or die.

Heat Exhaustion

This is one of the most common consequence of being out under the hot sun. Dehydration with prolonged heat exposure can lead to heat exhaustion.

Heatstroke

When you are out under the sun and your body's core temperature cross 104°, heatstroke may occur. This is also known as sunstroke. As per the Centers for Disease Control and Prevention (CDC), it causes more than 600 deaths each year in the United States.

An experimental bird flu vaccine designed by researchers using artificial intelligence (AI) has shown significant promise. It provided complete protection against multiple virus variants in animal-based trials. It outperformed existing vaccines stockpiled by governments for a human outbreak.

Developed by researchers at the University of Cambridge and its spin-off company DIOSynVax, the broad-spectrum vaccine protected mice and ferrets against various variants of bird flu virus that were genetically diverse. In comparison, the existing vaccine used in the study protected only around 50% of the animals exposed to the same variants.

The findings were published in the journal Cell Reports Medicine recently. The researchers say the findings could help improve preparedness for future influenza outbreaks. The vaccine is yet to be tested in humans.

“Rather than providing immunity to a single variant of bird flu, our new broad-spectrum vaccine is protective against a huge range of variants. It’s designed to counteract viral evolution, rather than reacting to it,” said Professor Jonathan Heeney, who led the research at the University of Cambridge's Department of Veterinary Medicine.

Bird Flu Vaccine Designed Using AI

Also read: Bird Flu In Humans: 2 Cases, 1 Death In Washington; Experts Warn Of H5N1 Spread And Viral Evolution

Traditional vaccines often target specific virus strains that have already emerged and infected humans. However, influenza viruses can mutate rapidly, which could reduce the effectiveness of vaccines made for earlier variants.

The researchers collected genetic sequence data from bird flu viruses recorded through global surveillance programmes to tackle this challenge. These included samples from wildlife, livestock and infected humans.

They then used AI to analyse the large datasets and identify antigen features shared across different viruses. Antigens are the components of a vaccine that stimulate the immune system to identify and respond to a pathogen.

The researchers then used this information to design synthetic antigens, which were screened in laboratory tests before the most promising candidate was selected for animal trials.

“Using AI vastly speeds up the process of vaccine design, and then we can test the vaccine candidates in the lab to make sure they’re robust and safe,” Heeney said.

Dr Sneha Vishwanath, a member of the research team, explained that the vaccine's antigens were designed to target multiple stages of the virus's lifecycle. “By instructing the immune system to target different stages of the viral lifecycle, we can induce an immune response blocking several crucial steps in its replication,” she said.

What Did The Animal Study Find?

Also read: AI-Created Virus Injected Into A Human For The First Time To Fight Antibiotic Resistance

The experimental bird flu vaccine provided complete protection to mice and ferrets that were exposed to various genetically diverse bird flu variants. These variants have all been linked with human infections and are considered major pandemic threats.

By comparison, only around 50% of the animals survived exposure when they were given the World Health Organization's existing bird flu vaccine.

The researchers said the findings suggest that a vaccine designed to target features shared across multiple virus variants could offer better protection than one developed against a particular strain.

Human Trials Remain

The vaccine has only been tested in animal trials. Human clinical trials are the next step in the protocol. Its safety and effectiveness in people will need to be established before it can be considered for use.

Bird flu, also known as avian influenza, is an infectious disease caused by influenza viruses that primarily affect birds but can sometimes infect mammals, including humans. Some human infections can be mild while other variants have caused severe illness and deaths.

The researchers believe developing vaccines that protect against a wider range of variants could help reduce the risks posed by emerging infections.

“It’s when bird flu adapts to live in the airways of mammals that we start to get really nervous,” Heeney said. “If we can make better animal vaccines, then we can better protect human health as well.”

The US Food and Drug Administration (FDA) is investigating a possible cancer risk linked to Novartis' gene therapy Zolgensma after the Swiss drugmaker reported several cases of tumours in patients who had received the treatment. It included two patients aged less than two years old with spinal muscular atrophy (SMA) in which investigators found evidence linking the tumour to the therapy.

Novartis's SMA Drug Under Investigation For Causing Tumour Growth

Zolgensma is a one-time gene therapy used to treat children under two years of age with spinal muscular atrophy (SMA), a rare genetic disorder that causes progressive muscle weakness. More than 6,000 patients have received the treatment since its approval in 2019.

In a safety update issued on November 6, the FDA said it had received reports of neoplasia, or tumour formation including malignancy, known as insertional oncogenesis. This occurs when genetic material delivered by a gene therapy becomes integrated into a patient's DNA and contributes to abnormal cell growth.

In two cases, molecular analysis of tumour tissue showed that DNA from the therapy's viral vector had integrated into the patients' genomes within the GLI1 gene, which can promote cancer when activated. The FDA said it was also investigating a third tumour linked with GLI1.

The agency said tumours had been found in the central and peripheral nervous systems, spinal and paraspinal regions, and kidney.

Also read: Drug-Resistant Epileptic Seizures Reduce By Over 90% With Experimental Gene Therapy

What Has The FDA Said About The Risk?

The FDA is assessing whether regulatory action is needed and is reviewing whether the long-term safety studies address the risk.

However, it stressed that the benefits of both Zolgensma and Novartis' other SMA gene therapy, Itvisma, continue to outweigh their potential risks for their approved uses.

The two therapies use the same viral vector and genetic material but are administered differently. Zolgensma is given through an intravenous infusion to children under two, while Itvisma is injected into the spinal canal and is approved for adults and children aged two and older. The FDA said no cases of tumour formation had been reported following Itvisma treatment so far.

The risk of tumour formation due to viral DNA integration is already mentioned in Zolgensma's information as a theoretical risk. The FDA said patients receiving either treatment should be monitored for tumour formation.

Also read: India Proposes Stricter Drug Rules: Tougher Quality Checks, Licence Suspension

What Novartis Said?

Novartis said the two patients whose tumours showed evidence of vector DNA integration had undergone treatment and continued to be monitored.

In a statement, the company said, “Patient safety is our priority. In each case, we timely and appropriately notified health authorities and will continue to work with them on next steps.”

The company also said it had received nine tumour reports since Zolgensma's approval and that the risk was included in the drug's prescribing information.

The disclosures have raised questions among families and patients about when the information was shared. SMA Europe urged the company to explain what is known, what remains uncertain and what the findings could mean for children who have already received treatment. Novartis did not provide details on where the two new cases were in its statement.

The United States is in the midst of one of the worst measles outbreak. It has reported more than 5,000 measles cases in 2026, marking the highest annual total cases since 1991.

This has raised concerns that the country could lose its measles elimination status after more than 25 years.

Measles Cases In The US Cross 5,000

Also read: EXCLUSIVE: Ex-CDC Vaccine Advisor Says Measles Outbreak Bigger Than Reported, Slams RFK Jr’s ‘No-See Evil’ Approach

According to an update issued on November 6, the US Centers for Disease Control and Prevention (CDC) reported 5,182 confirmed cases as of November 5. This is the first time since 1991 that the annual number of infections has crossed the 5,000 mark.

The latest figure marks an increase of 330 cases from the previous week. The CDC also reported 562 hospitalisations due to measles this year, which accounts for 11% of confirmed cases.

The outbreak has spread across 47 jurisdictions and 43 outbreaks reported so far in 2026. Approximately around 96% of infections have been linked to outbreaks, while 96% of people infected were either unvaccinated or their vaccination status was unknown.

The expanding measles outbreak has sparked concerns about the country's ability to maintain the elimination status it achieved in 2000.

Could The US Lose Its Measles Elimination Status?

Also read: 'It’s The Best-Studied Vaccine In Human History': Former CDC Adviser Busts Common Myths About COVID Vaccines

The US declared measles eliminated in 2000, meaning that the country had stopped continuous transmission of the virus for at least 12 months, but infections could still occur when people brought the virus into the country from abroad. However, recent outbreaks have raised concerns that measles could become endemic again.

According to the CDC, elimination status is determined by the absence of continuous measles transmission in a geographical area for 12 months or longer, supported by an effective disease surveillance system.

The United States is facing a review of its elimination status by the Pan American Health Organization (PAHO), which is expected to assess the country's progress in controlling transmission during its November 2026 meeting.

The review will examine whether the ongoing outbreaks represent sustained transmission of the virus and whether the country continues to meet the criteria for elimination. Losing elimination status would that the country had failed to interrupt sustained transmission of the virus.

The Americas region had already lost its measles elimination status in November 2025 after Canada experienced continuous transmission for at least 12 months.

What Happens If The US Loses Its Elimination Status?

Also read: US Midterms: Where Did Voters Support Abortion Rights And Where Did They Reject Them?

Losing measles elimination status would mark a major setback for public health efforts that successfully interrupted continuous measles transmission in the country in 2000.

It would also signal that the virus is circulating continuously within the population rather than appearing mainly through imported infections that cause outbreaks that get eventually contained.

However, elimination status can be regained if sustained transmission is interrupted and the required criteria are met. Public health experts continue to emphasise the importance of maintaining high vaccination coverage, identifying cases quickly and responding to outbreaks promptly.

Who Is Being Affected By The US Measles Outbreak?

The latest CDC data show that measles is affecting people across different age groups. Adults aged 20 and older accounted for 2,132 cases, followed by 2,104 infections among people aged five to 19. Children younger than five accounted for 908 cases.

The CDC reported four measles deaths in 2026, compared with three during the whole of 2025. However, the CDC's national death count differs from figures reported by individual state health departments because the agency uses National Center for Health Statistics mortality data for its official tally.

Pennsylvania has been among the hardest-hit states, reporting 1,487 cases, 287 hospitalisations and six associated deaths, according to Reuters. The outbreak has also spread to South Carolina and Utah, which reported 670 and 536 cases, respectively.

According to state health department reports, the country has recorded eight measles-related deaths this year: six in Pennsylvania, one in New York and one in Wisconsin. At least four involved children or infants.